Saltigo expands production with investment from Syngenta
Syngenta invests around €50m to boost capacity for synthesising active ingredients
Syngenta, a leading Swiss manufacturer of crop protection agents, is investing around €50m to expand several Saltigo facilities to boost its capacity for synthesising active ingredients for crop protection agents. Saltigo supplies the active ingredients and intermediates produced at these facilities exclusively to Syngenta.
‘This long-term cooperation underlines the enormous confidence Syngenta has in Saltigo’s expertise and technology as a specialist in synthesis chemistry,’ said Axel Heitmann, board chairman of Lanxess. ‘The expansion in capacity will also give a major boost to Leverkusen’s long-term future as a location for high-tech chemistry.’
John Ramsay, Syngenta’s chief financial officer, added: ‘The substantial investment here at the site shows a clear commitment to our collaboration, which already extends back more than 15 years.’
Three facilities are being expanded with the installation of new synthesis reactors, which will be built while the existing systems continue to work at full capacity. The expansion is due to be completed at the end of the year.
Saltigo offers tailor made end-to-end solutions for customers from the crop protection and pharmaceutical sectors as well as for various non-life science industries. The compounds form the basis of numerous pharmaceutical and agro active ingredients, polymers and specialist chemicals.
Saltigo is part of the Advanced Intermediates division of Lanxess, which generated sales of €1.1bn in fiscal 2009. The company, headquartered in Langenfeld and with production facilities in Leverkusen and Dormagen, employs around 1,350 people in Germany.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.